Amanda Smith

Amanda Smith has a diverse work experience spanning various companies and roles. Amanda is currently the Chief Executive Officer at Pencil Biosciences Limited and the Head of IP at Epitopea, both roles they started in 2022. Prior to these positions, Amanda worked at Horizon Discovery, a PerkinElmer Company, as the Head of IP and Licensing from December 2016 to April 2022. In this role, they were responsible for in and out licensing, technology scouting, IP, and innovation management. Before Horizon Discovery, Amanda was a Manager Research - Innovation at Sanofi from June 2013 to April 2016, where they provided scientific and medical direction for Consumer Healthcare Division operations and product innovation. From November 2007 to June 2013, they worked at CCA Therapeutics as the Director and Company Secretary, leading the commercialization of a platform technology for conotoxin peptides. Amanda also held the position of Manager, Commercialization and Intellectual Property at UniQuest Pty Ltd and IMBcom Pty Ltd from January 2006 to June 2013. Amanda'searlier experience includes working as a Patent and Trademark Attorney at Fisher Adams Kelly from February 2002 to January 2006.

Amanda Smith holds a DPhil in neuroscience, physiology, and pharmacology from the University of Oxford, although the specific years of study are unknown. Amanda also obtained a Masters degree in Intellectual Property Law from the University of Technology Sydney, completing their studies from 2003 to 2005. Prior to their Masters degree, they pursued a Bachelor's Degree in Pharmacology at The University of Manchester, without specific start and end years provided. Additionally, Amanda has a certification called Graduate Australian Institute Company Directors, obtained from the Australian Institute of Company Directors, but the month and year of its acquisition are not specified.